ASH 2019 | Fedratibib improves HRQoL in myelofribrosis

Ruben Mesa

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, explains the effect of fedratinib on patient-reported myelofibrosis (MF) associated symptoms and health-related quality of life in the JAKARTA study (NCT01437787). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter